[
    {
        "pregunta": "1. What are the first-line therapies recommended for gout flares according to the 2020 American College of Rheumatology Guideline?",
        "respuesta": "According to the 2020 American College of Rheumatology Guideline, the recommended first-line therapies for gout flares include oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular). The choice among these should be made based on patient factors and preferences.",
        "contexto": [
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|",
            "recommended for patients experiencing a gout flare for whom the above antiinflammatory therapies are either ineffective, poorly tolerated, or contraindicated. Treatment with glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH is strongly recommended for patients who are unable to take oral medications. The Voting Panel's recommendation of colchicine, NSAIDs, or glucocorticoids as preferred first-line therapies was based on substantial trial data",
            "obese, regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences). When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose",
            "is not absolute and not meant to be pursued at \"any cost.\" Even strong recommendations require sound clinical judgment to balance the potential clinical benefits and harms (including costs) of medical decisions Gout flare management Using colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate firstline therapy for gout flares over IL-1 inhibitors or adrenocorticotropic hormone (ACTH) is strongly recommended for patients experiencing a gout flare. Given",
            "rt/Clini cal-Pract ice-Guide lines https://www.rheum atolo gy. org/Pract ice-Quali ty/Clini cal-Suppo rt/Clini cal-Pract ice-Guide lines/ Gout http://onlin elibr ary.wiley.com/doi/10.1002/acr.24180/ abstract Briefly, the Core Team, Expert Panel, and Voting Panel (consisting of rheumatologists, a general internist, a nephrologist, a physician assistant, and a patient representative) generated 57 population, intervention, comparator, and outcomes (PICO) questions to address the following:"
        ]
    },
    {
        "pregunta": "2. How is the choice between colchicine, NSAIDs, and glucocorticoids determined in the management of gout flares?",
        "respuesta": "The choice between colchicine, NSAIDs, and glucocorticoids for the management of gout flares, as recommended by the 2020 American College of Rheumatology Guideline, should be made based on patient factors and preferences. Factors that can influence this decision may include the patient's medical history, comorbid conditions, potential drug interactions, renal function, gastrointestinal tolerance, and the presence of contraindications to any of these medications. The guideline does not provide specific criteria for choosing one over the others, emphasizing the importance of individualized treatment based on clinical judgment and patient-specific considerations.",
        "contexto": [
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|",
            "is not absolute and not meant to be pursued at \"any cost.\" Even strong recommendations require sound clinical judgment to balance the potential clinical benefits and harms (including costs) of medical decisions Gout flare management Using colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate firstline therapy for gout flares over IL-1 inhibitors or adrenocorticotropic hormone (ACTH) is strongly recommended for patients experiencing a gout flare. Given",
            "obese, regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences). When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose",
            "recommended for patients experiencing a gout flare for whom the above antiinflammatory therapies are either ineffective, poorly tolerated, or contraindicated. Treatment with glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH is strongly recommended for patients who are unable to take oral medications. The Voting Panel's recommendation of colchicine, NSAIDs, or glucocorticoids as preferred first-line therapies was based on substantial trial data",
            "the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects. High † For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/ analgesic treatment). Moderate For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or"
        ]
    },
    {
        "pregunta": "3. What is the recommendation for using IL-1 inhibitors in patients with gout flares who cannot tolerate other anti-inflammatory therapies?",
        "respuesta": "According to the 2020 American College of Rheumatology Guideline, for patients experiencing a gout flare who cannot tolerate other anti-inflammatory therapies or for whom these therapies are contraindicated, it is conditionally recommended to use IL-1 inhibitors over no therapy (beyond supportive or analgesic treatment). The certainty of evidence supporting this recommendation is moderate.",
        "contexto": [
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|",
            "recommended for patients experiencing a gout flare for whom the above antiinflammatory therapies are either ineffective, poorly tolerated, or contraindicated. Treatment with glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH is strongly recommended for patients who are unable to take oral medications. The Voting Panel's recommendation of colchicine, NSAIDs, or glucocorticoids as preferred first-line therapies was based on substantial trial data",
            "|When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects.| | |\n|For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/analgesic treatment).|33|Moderate|",
            "the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects. High † For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/ analgesic treatment). Moderate For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or",
            "of potential benefits outweighs the harms and costs of the drug. ‡ For patients with minimal disease activity, the smaller potential benefits do not outweigh the harms and costs of the drug. Using topical ice as an adjuvant treatment over no adjuvant treatment is conditionally recommended for patients experiencing a gout flare. Using an IL-1 inhibitor over no therapy (beyond supportive/analgesic treatment) is conditionally recommended for patients experiencing a gout flare for whom the above"
        ]
    },
    {
        "pregunta": "4. What is the preferred adjuvant treatment for gout flares, according to the guideline?",
        "respuesta": "According to the 2020 American College of Rheumatology Guideline, using topical ice as an adjuvant treatment is conditionally recommended for patients experiencing a gout flare over no adjuvant treatment.",
        "contexto": [
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|",
            "recommended for patients experiencing a gout flare for whom the above antiinflammatory therapies are either ineffective, poorly tolerated, or contraindicated. Treatment with glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH is strongly recommended for patients who are unable to take oral medications. The Voting Panel's recommendation of colchicine, NSAIDs, or glucocorticoids as preferred first-line therapies was based on substantial trial data",
            "of potential benefits outweighs the harms and costs of the drug. ‡ For patients with minimal disease activity, the smaller potential benefits do not outweigh the harms and costs of the drug. Using topical ice as an adjuvant treatment over no adjuvant treatment is conditionally recommended for patients experiencing a gout flare. Using an IL-1 inhibitor over no therapy (beyond supportive/analgesic treatment) is conditionally recommended for patients experiencing a gout flare for whom the above",
            "obese, regardless of disease activity. Certainty of evidence For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences). When colchicine is the chosen agent, we strongly recommend low-dose colchicine over high-dose",
            "is not absolute and not meant to be pursued at \"any cost.\" Even strong recommendations require sound clinical judgment to balance the potential clinical benefits and harms (including costs) of medical decisions Gout flare management Using colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate firstline therapy for gout flares over IL-1 inhibitors or adrenocorticotropic hormone (ACTH) is strongly recommended for patients experiencing a gout flare. Given"
        ]
    },
    {
        "pregunta": "5. What lifestyle factors are conditionally recommended to be limited in patients with gout?",
        "respuesta": "According to the 2020 American College of Rheumatology Guideline, for patients with gout, it is conditionally recommended to limit the intake of alcohol, purines, and high-fructose corn syrup. Additionally, weight loss is conditionally recommended for overweight or obese patients with gout. These recommendations are supported by varying levels of certainty of evidence, ranging from low to very low.",
        "contexto": [
            "in these guidelines are supported by higher quality studies than the 2012 ACR Guidelines for the Management of Gout. This resulted in a more focused, less proscriptive document. Where certainty of data is less than moderate or high, conditional recommendations made herein are meant to highlight those decisions that would benefit from a shared patient-provider decision-making process. This would include areas such as diet, lifestyle, or concomitant medications that might affect SU levels, and",
            "<p>|Recommendation|PICO|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting alcohol intake.|41|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting purine intake.|42|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting high-fructose corn syrup.|43|Very low|",
            "for patients with gout, regardless of disease activity. Limiting purine intake is conditionally recommended for patients with gout, regardless of disease activity. Limiting high-fructose corn syrup intake is conditionally recommended for patients with gout, regardless of disease activity. Using a weight loss program (no specific program endorsed) is conditionally recommended for those patients with gout who are overweight/ obese, regardless of disease activity. Certainty of evidence For",
            "lifestyle, or concomitant medications that might affect SU levels, and for which the Patient Panel requested guidance. The Voting Panel aimed to provide guidance without implying any \"patient-blaming\" for the manifestations of gout given its strong genetic determinants. Indications for ULT are expanded from the 2012 ACR Guidelines for the Management of Gout, but consistent with the 2016 update of the EULAR gout recommendations This updated guideline effort also identifies several areas that",
            "|For overweight/obese patients with gout, regardless of disease activity, we conditionally recommend weight loss.|46|Very low|\n|For patients with gout, regardless of disease activity, we conditionally recommend against adding vitamin C supplementation.|48|Low|</p>"
        ]
    },
    {
        "pregunta": "6. What is the recommendation regarding the use of vitamin C supplementation in patients with gout?",
        "respuesta": "According to the 2020 American College of Rheumatology Guideline, for patients with gout, regardless of disease activity, it is conditionally recommended against adding vitamin C supplementation. The certainty of evidence supporting this recommendation is low.",
        "contexto": [
            "|For overweight/obese patients with gout, regardless of disease activity, we conditionally recommend weight loss.|46|Very low|\n|For patients with gout, regardless of disease activity, we conditionally recommend against adding vitamin C supplementation.|48|Low|</p>",
            "<p>|Recommendation|PICO|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting alcohol intake.|41|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting purine intake.|42|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting high-fructose corn syrup.|43|Very low|",
            "in these guidelines are supported by higher quality studies than the 2012 ACR Guidelines for the Management of Gout. This resulted in a more focused, less proscriptive document. Where certainty of data is less than moderate or high, conditional recommendations made herein are meant to highlight those decisions that would benefit from a shared patient-provider decision-making process. This would include areas such as diet, lifestyle, or concomitant medications that might affect SU levels, and",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|",
            "2020 American College of Rheumatology Guideline for the Management of Gout  FACP  American College of Rheumatology      F80A3E8AB0860BDC6587873AB54E2F45 10.1002/acr.24180 received research support from Hikma Pharmaceuticals and Horizon Pharma. Dr. Singh has received consulting fees, speaking fees, and/or honoraria from Crealta/ Horizon, Medisys, Fidia, UBM, Trio Health, Medscape, WebMD, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Spherix, and Practice Point"
        ]
    },
    {
        "pregunta": "7. When should hydrochlorothiazide be switched to an alternate antihypertensive in patients with gout?",
        "respuesta": "According to the 2020 American College of Rheumatology Guideline, it is conditionally recommended to switch hydrochlorothiazide to an alternate antihypertensive for patients with gout, regardless of disease activity, when feasible. The certainty of evidence supporting this recommendation is very low.",
        "contexto": [
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend switching hydrochlorothiazide to an alternate antihypertensive when feasible.|47|Very low|\n|We conditionally recommend choosing losartan preferentially as an antihypertensive when feasible.|47|Very low|",
            "weight increases SU concentration by 1-2 mg/dl within 2 hours of ingestion Weight loss. The Voting Panel considered the impact of weight loss and specific dietary programs (including the DASH diet Management of concurrent medications Switching hydrochlorothiazide to an alternate antihypertensive when feasible is conditionally recommended for patients with gout, regardless of disease activity. Choosing losartan preferentially as an antihypertensive agent when feasible is conditionally",
            "<p><strong>Table 2. Recommendations for choice of initial urate-lowering therapy (ULT) in patients with gout*</strong>\n|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients starting any ULT, we strongly recommend allopurinol over all other ULT as the preferred first-line agent for all patients, including in those with CKD stage &gt;3.|10|Moderate|\n|We strongly recommend a xanthine oxidase inhibitor over probenecid for those with CKD stage &gt;3.| | |",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients with gout taking their first XOI monotherapy at maximum-tolerated or FDA-indicated dose who are not at SU target and/or have continued frequent gout flares or nonresolving subcutaneous tophi, we conditionally recommend switching the first XOI to an alternate XOI agent over adding a uricosuric agent.|24|Very low|",
            "preferentially as an antihypertensive agent when feasible is conditionally recommended for patients with gout, regardless of disease activity. Stopping low-dose aspirin (for patients taking this medication for appropriate indications) is conditionally recommended against for patients with gout, regardless of disease activity. Adding or switching cholesterol-lowering agents to fenofibrate is conditionally recommended against for patients with gout, regardless of disease activity. Medications"
        ]
    },
    {
        "pregunta": "8. What is the recommended antihypertensive agent of choice for patients with gout?",
        "respuesta": "According to the 2020 American College of Rheumatology Guideline, losartan is conditionally recommended preferentially as an antihypertensive agent for patients with gout when feasible. The certainty of evidence supporting this recommendation is very low.",
        "contexto": [
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend switching hydrochlorothiazide to an alternate antihypertensive when feasible.|47|Very low|\n|We conditionally recommend choosing losartan preferentially as an antihypertensive when feasible.|47|Very low|",
            "<p>|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients experiencing a gout flare, we strongly recommend using oral colchicine, NSAIDs, or glucocorticoids (oral, intraarticular, or intramuscular) as appropriate first-line therapy for gout flares over IL-1 inhibitors or ACTH (the choice of colchicine, NSAIDs, or glucocorticoids should be made based on patient factors and preferences).|32|High†|",
            "preferentially as an antihypertensive agent when feasible is conditionally recommended for patients with gout, regardless of disease activity. Stopping low-dose aspirin (for patients taking this medication for appropriate indications) is conditionally recommended against for patients with gout, regardless of disease activity. Adding or switching cholesterol-lowering agents to fenofibrate is conditionally recommended against for patients with gout, regardless of disease activity. Medications",
            "<p><strong>Table 2. Recommendations for choice of initial urate-lowering therapy (ULT) in patients with gout*</strong>\n|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients starting any ULT, we strongly recommend allopurinol over all other ULT as the preferred first-line agent for all patients, including in those with CKD stage &gt;3.|10|Moderate|\n|We strongly recommend a xanthine oxidase inhibitor over probenecid for those with CKD stage &gt;3.| | |",
            "recommended for patients experiencing a gout flare for whom the above antiinflammatory therapies are either ineffective, poorly tolerated, or contraindicated. Treatment with glucocorticoids (intramuscular, intravenous, or intraarticular) over IL-1 inhibitors or ACTH is strongly recommended for patients who are unable to take oral medications. The Voting Panel's recommendation of colchicine, NSAIDs, or glucocorticoids as preferred first-line therapies was based on substantial trial data"
        ]
    },
    {
        "pregunta": "9. What is the recommendation regarding low-dose aspirin in patients with gout who are taking it for appropriate indications?",
        "respuesta": "According to the 2020 American College of Rheumatology Guideline, for patients with gout, regardless of disease activity, it is conditionally recommended against stopping low-dose aspirin when a patient is taking it for appropriate indications. Recognizing that there are few practical alternatives to low-dose aspirin, the guideline specifically recommends against its cessation as a means of reducing serum urate (SU) levels when it is being used for appropriate indications.",
        "contexto": [
            "preferentially as an antihypertensive agent when feasible is conditionally recommended for patients with gout, regardless of disease activity. Stopping low-dose aspirin (for patients taking this medication for appropriate indications) is conditionally recommended against for patients with gout, regardless of disease activity. Adding or switching cholesterol-lowering agents to fenofibrate is conditionally recommended against for patients with gout, regardless of disease activity. Medications",
            "for patients with gout, regardless of disease activity. Medications noted above are known to have effects on SU concentrations Recognizing that there are few practical alternatives to lowdose aspirin, the Voting Panel specifically recommended against its cessation as a means of SU reduction when a patient is taking it for an appropriate indication. Likewise, the Voting Panel specifically recommended against adding or switching cholesterollowering agents (e.g., statins, bile acid sequestrants,",
            "the chosen agent, we strongly recommend low-dose colchicine over high-dose colchicine given its similar efficacy and fewer adverse effects. High † For patients experiencing a gout flare for whom other antiinflammatory therapies are poorly tolerated or contraindicated, we conditionally recommend using IL-1 inhibition over no therapy (beyond supportive/ analgesic treatment). Moderate For patients who may receive NPO, we strongly recommend glucocorticoids (intramuscular, intravenous, or",
            "<p>|Recommendation|PICO|Certainty of evidence|\n|---|---|---|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting alcohol intake.|41|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting purine intake.|42|Low|\n|For patients with gout, regardless of disease activity, we conditionally recommend limiting high-fructose corn syrup.|43|Very low|",
            "in these guidelines are supported by higher quality studies than the 2012 ACR Guidelines for the Management of Gout. This resulted in a more focused, less proscriptive document. Where certainty of data is less than moderate or high, conditional recommendations made herein are meant to highlight those decisions that would benefit from a shared patient-provider decision-making process. This would include areas such as diet, lifestyle, or concomitant medications that might affect SU levels, and"
        ]
    },
    {
        "pregunta": "10. What are the indications for initiating pharmacologic urate-lowering therapy (ULT) in patients with gout according to the guideline?",
        "respuesta": "According to the 2020 American College of Rheumatology Guideline, initiating pharmacologic urate-lowering therapy (ULT) is strongly recommended for gout patients with any of the following: the presence of ≥1 subcutaneous tophi.",
        "contexto": [
            "<h1>Table 1. Indications for pharmacologic urate-lowering therapy (ULT)*</h1>",
            "course of guideline development, it remains Food and Drug Administration (FDA) approved, and we therefore considered the data in relation to relevant PICO questions. To facilitate the 2 NMAs, we also considered medications not available in the US to permit comparisons with other available medications in the network analysis. | 747 RESULTS/RECOMMENDATIONS Indications for pharmacologic ULT Initiating ULT is strongly recommended for gout patients with any of the following: ≥1 subcutaneous tophi;",
            "<p><strong>Table 2. Recommendations for choice of initial urate-lowering therapy (ULT) in patients with gout*</strong>\n|Recommendation|PICO question|Certainty of evidence|\n|---|---|---|\n|For patients starting any ULT, we strongly recommend allopurinol over all other ULT as the preferred first-line agent for all patients, including in those with CKD stage &gt;3.|10|Moderate|\n|We strongly recommend a xanthine oxidase inhibitor over probenecid for those with CKD stage &gt;3.| | |",
            "gout flares or subcutaneous tophi), we conditionally recommend against initiating any pharmacologic ULT (allopurinol, febuxostat, probenecid) over initiation of pharmacologic ULT. 57 High † * PICO = population, intervention, comparator, outcomes; CKD = chronic kidney disease; SU = serum urate. † There is randomized clinical trial data to support the benefit that ULT lowers the proportion of patients who develop incident gout. However, based on the attributable risk, 24 patients would need to be",
            "lifestyle, or concomitant medications that might affect SU levels, and for which the Patient Panel requested guidance. The Voting Panel aimed to provide guidance without implying any \"patient-blaming\" for the manifestations of gout given its strong genetic determinants. Indications for ULT are expanded from the 2012 ACR Guidelines for the Management of Gout, but consistent with the 2016 update of the EULAR gout recommendations This updated guideline effort also identifies several areas that"
        ]
    }
]